<DOC>
	<DOC>NCT00372112</DOC>
	<brief_summary>The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers. This study will assess the safety and tolerability of GW642444 in subjects with COPD in order to obtain information to support dosing in a broader population of subjects with COPD</brief_summary>
	<brief_title>A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 administered once daily in the morning via DISKUSâ„¢ dry-powder inhaler) compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: females must be of nonchildbearing potential moderately severe COPD Exclusion criteria: Subjects with a main diagnosis of asthma subjects with poorly controlled COPD subjects with significant heart, renal, endocrine, psychiatric, immunological or neurological disease.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>COPD</keyword>
</DOC>